Sign up to save your podcasts
Or
Share Niraparib + Abiraterone, Elranatamab, & Melphalan Updates
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Niraparib + Abiraterone, Elranatamab, & Melphalan Updates
A combination product is now available of niraparib + abiraterone for use in mCRPC.
Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.
View all episodes
By John Bossaer
4.9
181181 ratings
A combination product is now available of niraparib + abiraterone for use in mCRPC.
Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.
More shows like OncoPharm
View all
JAMA Clinical Reviews
495 Listeners
ASCO Daily News
57 Listeners
White Coat Investor Podcast
2,440 Listeners
The Curbsiders Internal Medicine Podcast
3,333 Listeners
Core IM | Internal Medicine Podcast
1,151 Listeners
The ONS Podcast
197 Listeners
ASCO Guidelines
44 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
712 Listeners
OncLive® On Air
22 Listeners
Oncology Today with Dr Neil Love
57 Listeners
The Curious Clinicians
369 Listeners
Ninja Nerd
318 Listeners
Two Onc Docs
189 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
WolverHeme Happy Hour
30 Listeners